Investigation of the Effect of Myokine on Immunotherapeutic Efficacy and Safety in Patients with Non-Small Cell Lung Cancer

2022 Fiscal Year Final Research Report

• Project/Area Number: 20K16432
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 50020:Tumor diagnostics and therapeutics-related
• Research Institution: National Hospital Organization, Kyushu Cancer Center
• Principal Investigator: Takamori Shinkichi 独立行政法人国立病院機構(九州がんセンター臨床研究センター), その他部局等, 呼吸器腫瘍科医師 (20839542)
• Project Period (FY): 2020-04-01 – 2023-03-31
• Keywords: マイオカイン / サルコペニア / 骨格筋 / 肺癌 / 免疫チェックポイント阻害薬 / バイオマーカー

Outline of Final Research Achievements

Skeletal muscle area was measured on pretreatment CT images. Blood myokines were measured comprehensively for 15 types using Filgen's MILLIPLEX Human Myokine Panel. When 123 blood samples were submitted to Filgen, 10 of the 15 myokines were found to be almost below detection sensitivity. Among the 5 myokines that were measurable, SPARC (secreted protein acidic and rich in cysteine) correlated with skeletal muscle mass and tended to be higher in patients who responded to immunotherapy. These results were presented at the 63rd Annual Meeting of the Japanese Lung Cancer Association, Scientific Committee Symposium Session, and are currently being discussed.

Free Research Field

呼吸器外科

Academic Significance and Societal Importance of the Research Achievements

本研究の結果、マイオカインのSPARC (secreted protein acidic and rich in cysteine)が免疫治療効果と関係することが明らかとなった。この結果から、骨格筋量減少（サルコペニア）を有する患者に対する解決策に繋がることが期待される。今後、サルコペニアの肺癌患者にマイオカインのSPARC を補充する新規薬剤開発に繋がる可能性がある。サルコペニアの肺癌患者に対する様々な介入試験を行う際の重要なrationaleとなると考えられ、肺癌免疫療法や肺癌悪液質の領域におけるBreakthroughに繋がる可能性がある。